Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 20/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL66599 | 1.00 | ALOX5 (0.83) | ALOX5 | |
| SCHEMBL16430159 | 1.00 | ALOX5 (0.83) | ALOX5 | |
| SCHEMBL2365123 | 1.00 | ALOX5 (0.83) | ALOX5 | |
| Hydroquinone SCHEMBL116980 | 0.96 | ALOX5 (0.77) | ALOX5 | |
| Benzoquinone SCHEMBL119191 | 0.94 | ALOX5 (0.76) | ALOX5 | |
| SCHEMBL11056496 | 0.92 | ALOX5 (0.70) | ALOX5 | |
| SCHEMBL10307486 | 0.91 | ALOX5 (0.70) | ALOX5 | |
| SCHEMBL18583996 | 0.91 | ALOX5 (1.00) | ALOX5 | |
| SCHEMBL18583997 | 0.91 | ALOX5 (1.00) | ALOX5 | |
| SCHEMBL18583921 | 0.90 | ALOX5 (1.00) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102053-A1 | FOAM ENHANCING PHOSPHOLIPID EMULSION SYSTEMS | ABSTRAX TECH INC. (US) | 2026-05-15 | — | — | WO | claimed |
| WO-2026102051-A1 | METHOD AND SYSTEM FOR STABILIZING EMULSIONS USING VITAMINS AND VITAMINS SALTS | ABSTRAX TECH INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20070183989-A1 | Oral Compositions Comprising Zinc Citrate and/or Tocopherol Agents | COLGATE-PALMOLIVE COMPANY | 2007-08-09 | — | — | US | claimed |
| WO-2026102051-A1 | METHOD AND SYSTEM FOR STABILIZING EMULSIONS USING VITAMINS AND VITAMINS SALTS | ABSTRAX TECH INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026102053-A1 | FOAM ENHANCING PHOSPHOLIPID EMULSION SYSTEMS | ABSTRAX TECH INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| CN-122055373-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260123640-A1 | METHOD AND SYSTEM FOR STABILIZING EMULSIONS USING VITAMINS AND VITAMINS SALTS | ABSTRAX TECH INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12377123-B2 | Preoperative compositions and methods of preparation thereof | Preoperative Nutrition (US) | 2025-08-05 | — | — | US | disclosed |
| WO-2025130061-A1 | OILY TACROLIMUS PREPARATION FOR TREATING DRY EYE SYNDROME AND METHOD FOR PREPARING SAME | 艾尔健康眼药(辽宁)有限公司 | 2025-06-26 | — | — | WO | disclosed |
| US-20250186319-A1 | ANAPLEROTIC COMPOSITIONS AND USES THEREOF | EXCELLA BIOSCIENTIFIC LTD (IL) | 2025-06-12 | — | — | US | disclosed |
| WO-2025080879-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20030100603-A1 | Tocopherol enriched compositions and amelioration of inflammatory symptoms | JOHNSON & JOHNSON CONSUMER INC. | 2003-05-29 | — | — | US | disclosed |
| US-6528042-B1 | Non-naturally-occurring compositions for use in amelioration of disruption of energy metabolism secondary to stress are described. These compositions comprise a flavonoid or derivative thereof and a synergist. Synergists include such as | GALILEO LABORATORIES, INC. | 2003-03-04 | — | — | US | disclosed |
| US-20030022818-A1 | Formulations of tocopherols and methods of making and using them | ALLOY VENTURES, INC. | 2003-01-30 | — | — | US | disclosed |
| US-20020143049-A1 | Compositions and methods for the prevention and treatment of cerebral ischemia | PTC THERAPEUTICS, INC. | 2002-10-03 | — | — | US | disclosed |
| US-20020132845-A1 | Compositions and methods for the prevention and treatment of tissue ischemia | ALLOY VENTURES, INC. | 2002-09-19 | — | — | US | disclosed |
| US-6441029-B1 | D-.GAMMA.-TOCOTRIENOL, 2-DESMETHYLTOCOTRIENOL, D-.DELTA.-TOCOTRIENOL OR D-TOCOTRIENOL AND LOVASTATIN | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2002-08-27 | — | — | US | disclosed |
| US-6426362-B1 | RELIEVING CELL STRESS; SYNERGISTIC MIXTURE WITH FLAVONOIDS, TRANSFERRIN | GALILEO LABORATORIES, INC. | 2002-07-30 | — | — | US | disclosed |
| US-6265425-B1 | SIDE EFFECT REDUCTION; RETINOIC ACID METABOLISM BLOCKING AGENT | JANSSEN PHARMACEUTICA, N.V. (BE) | 2001-07-24 | — | — | US | disclosed |
| EP-1044687-A1 | POWDERS CONTAINING TOCOTRIENOLS, PROCESS FOR PRODUCING THE SAME AND TABLETS PREPARED BY COMPRESSION MOLDING THE SAME | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2000-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143049-A1 | Compositions and methods for the prevention and treatment of cerebral ischemia | EBP, NDUFB3, ECH1 | ALOX5 281/4885 |
| US-20260123640-A1 | METHOD AND SYSTEM FOR STABILIZING EMULSIONS USING VITAMINS AND VITAMINS SALTS | TTPA, PROC, ADH7 | ALOX5 100/4885 |
| US-20250186319-A1 | ANAPLEROTIC COMPOSITIONS AND USES THEREOF | OAT, PC, ACAT1 | ALOX5 479/4885 |
| US-20030100603-A1 | Tocopherol enriched compositions and amelioration of inflammatory symptoms | TTPA, TNNT2, GSR | ALOX5 35/4885 |
| US-20020132845-A1 | Compositions and methods for the prevention and treatment of tissue ischemia | NDUFB5, NDUFB3, EBP | ALOX5 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.